REGULATORY

Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW

July 29, 2026
Japanese Health Minister Kenichiro Ueno
Japanese Health Minister Kenichiro Ueno

A total of 46 medical facilities in Kumamoto Prefecture had reported damage following the magnitude 7.1 earthquake that struck southwestern Japan on July 28, while no drug makers or wholesalers had reported any damage as of 10:00 p.m., according to the health ministry.

Among the affected medical facilities, 15 were in Yatsushiro, followed by 10 in Uki and four in Kumamoto. Water outages were reported at 37 facilities, while 11 experienced power outages.

Although media reports have confirmed damage to roads, the Ministry of Health, Labor and Welfare (MHLW) said it had not yet received information indicating disruptions to pharmaceutical distribution. However, officials acknowledged at a press briefing that the damage could eventually affect medicine logistics.

Govt, MHLW Set Up Disaster Response Headquarters

Following the earthquake, the government established an emergency disaster response headquarters and held its first meeting.

Prime Minister Sanae Takaichi instructed ministries and agencies to work closely with local governments, quickly assess the overall extent of the damage and devote maximum efforts to emergency response activities, including rescue operations.

The MHLW subsequently convened its own disaster response headquarters. Health Minister Kenichiro Ueno instructed senior ministry officials to give top priority to four areas: rapidly assessing damage through all available channels, including local governments and relevant organizations, prioritizing lifesaving efforts by deploying Disaster Medical Assistance Teams (DMATs) and Disaster Psychiatric Assistance Teams (DPATs) while coordinating the availability of medical institutions to receive patients, strengthening welfare support for affected facilities and evacuation centers, and establishing a public-private support framework to secure medical supplies and other emergency response materials.

Related Article

REGULATORY

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Philip Carrigan

A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…

By Shinya Sato

Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…